Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18
出版年份 2016 全文链接
标题
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18
作者
关键词
-
出版物
BRITISH JOURNAL OF PHARMACOLOGY
Volume 173, Issue 9, Pages 1407-1424
出版商
Wiley
发表日期
2016-02-01
DOI
10.1111/bph.13450
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids
- (2015) Gregory S. Hamilton BIOLOGICALS
- The Concise Guide to PHARMACOLOGY 2015/16: Catalytic receptors
- (2015) Stephen PH Alexander et al. BRITISH JOURNAL OF PHARMACOLOGY
- The Concise Guide to PHARMACOLOGY 2015/16: Overview
- (2015) Stephen PH Alexander et al. BRITISH JOURNAL OF PHARMACOLOGY
- Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy
- (2015) V. Gonzalez-Nicolini et al. CLINICAL CANCER RESEARCH
- First-in-Human Phase I Study of Lumretuzumab, a Glycoengineered Humanized Anti-HER3 Monoclonal Antibody, in Patients with Metastatic or Advanced HER3-Positive Solid Tumors
- (2015) D. Meulendijks et al. CLINICAL CANCER RESEARCH
- Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
- (2015) H. J. Jacobsen et al. CLINICAL CANCER RESEARCH
- Bispecific antibodies
- (2015) Roland E. Kontermann et al. DRUG DISCOVERY TODAY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Programmed cell death-1 inhibition in lymphoma
- (2015) Eliza A Hawkes et al. LANCET ONCOLOGY
- Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
- (2015) Antoni Ribas et al. LANCET ONCOLOGY
- Safety and activity of the anti-CD79B antibody–drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study
- (2015) Maria Corinna A Palanca-Wessels et al. LANCET ONCOLOGY
- Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
- (2015) Max S Topp et al. LANCET ONCOLOGY
- Alternative molecular formats and therapeutic applications for bispecific antibodies
- (2015) Christoph Spiess et al. MOLECULAR IMMUNOLOGY
- Combination cancer immunotherapy and new immunomodulatory targets
- (2015) Kathleen M. Mahoney et al. NATURE REVIEWS DRUG DISCOVERY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer
- (2015) Pasi A. Jänne et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- An antibody to amphiregulin, an abundant growth factor in patients’ fluids, inhibits ovarian tumors
- (2015) S Carvalho et al. ONCOGENE
- Examination of HER3 targeting in cancer using monoclonal antibodies
- (2015) Nadège Gaborit et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer
- (2015) Maicol Mancini et al. Science Signaling
- Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
- (2015) R. Dienstmann et al. Cancer Discovery
- Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the “THERAPY”phase 1-2 trial
- (2015) Eric Assenat et al. Oncotarget
- Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer
- (2015) Maicol Mancini et al. Science Signaling
- In Pancreatic Carcinoma, Dual EGFR/HER2 Targeting with Cetuximab/Trastuzumab Is More Effective than Treatment with Trastuzumab/Erlotinib or Lapatinib Alone: Implication of Receptors' Down-regulation and Dimers' Disruption
- (2015) Christel Larbouret et al. NEOPLASIA
- Sym004, a Novel EGFR Antibody Mixture, Can Overcome Acquired Resistance to Cetuximab
- (2015) Mari Iida et al. NEOPLASIA
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial
- (2014) Ian E Krop et al. LANCET ONCOLOGY
- Tumor-Antigen–Binding Bispecific Antibodies for Cancer Treatment
- (2014) Ulrich H. Weidle et al. SEMINARS IN ONCOLOGY
- Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
- (2014) Y. Y. Janjigian et al. Cancer Discovery
- Combination of 4-1BB Agonist and PD-1 Antagonist Promotes Antitumor Effector/Memory CD8 T Cells in a Poorly Immunogenic Tumor Model
- (2014) S. Chen et al. Cancer Immunology Research
- Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives
- (2013) A. Milani et al. ANNALS OF ONCOLOGY
- Pertuzumab counteracts the inhibitory effect of ErbB2 on degradation of ErbB3
- (2013) Malgorzata Magdalena Sak et al. CARCINOGENESIS
- Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
- (2013) Zhiqiang Guo et al. Journal of Translational Medicine
- Myeloid cells as effector cells for monoclonal antibody therapy of cancer
- (2013) Rens Braster et al. METHODS
- Sym004, a Novel Anti-EGFR Antibody Mixture, Augments Radiation Response in Human Lung and Head and Neck Cancers
- (2013) S. Huang et al. MOLECULAR CANCER THERAPEUTICS
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
- (2013) Adam J. Pawson et al. NUCLEIC ACIDS RESEARCH
- Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR
- (2013) D. A. Ferraro et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2
- (2013) R. Maron et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Antibody-Drug Conjugates in Cancer Therapy
- (2012) Eric L. Sievers et al. Annual Review of Medicine
- Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation
- (2012) S. Huang et al. CANCER RESEARCH
- U.S. Food and Drug Administration Approval Summary: Brentuximab Vedotin for the Treatment of Relapsed Hodgkin Lymphoma or Relapsed Systemic Anaplastic Large-Cell Lymphoma
- (2012) R. A. de Claro et al. CLINICAL CANCER RESEARCH
- Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study
- (2012) Barbara Pro et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Rational identification of an optimal antibody mixture for targeting the epidermal growth factor receptor
- (2012) Klaus Koefoed et al. mAbs
- Dual targeting strategies with bispecific antibodies
- (2012) Roland Kontermann mAbs
- Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3
- (2012) C. F. McDonagh et al. MOLECULAR CANCER THERAPEUTICS
- Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
- (2012) Clara Montagut et al. NATURE MEDICINE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Monoclonal antibodies for the treatment of cancer
- (2012) Casey W. Shuptrine et al. SEMINARS IN CANCER BIOLOGY
- Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab
- (2011) Toni M. Brand et al. CANCER BIOLOGY & THERAPY
- A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies
- (2011) Gabriele Schaefer et al. CANCER CELL
- Antibody-Dependent Cell Cytotoxicity Synapses Form in Mice during Tumor-Specific Antibody Immunotherapy
- (2011) P. Hubert et al. CANCER RESEARCH
- Application of a novel inhibitor of human CD59 for the enhancement of complement-dependent cytolysis on cancer cells
- (2011) Tao You et al. Cellular & Molecular Immunology
- New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer
- (2011) G. R. Oxnard et al. CLINICAL CANCER RESEARCH
- Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites
- (2011) Marion G. Ott et al. INTERNATIONAL JOURNAL OF CANCER
- Cancer Immunotherapy Comes of Age
- (2011) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
- (2011) Luca Gianni et al. LANCET ONCOLOGY
- Cancer immunotherapy comes of age
- (2011) Ira Mellman et al. NATURE
- T cell exhaustion
- (2011) E John Wherry NATURE IMMUNOLOGY
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- Advances in the assessment and control of the effector functions of therapeutic antibodies
- (2011) Xu-Rong Jiang et al. NATURE REVIEWS DRUG DISCOVERY
- Antibodies in oncology
- (2011) Vinochani Pillay et al. New Biotechnology
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- (2011) K. Yonesaka et al. Science Translational Medicine
- Complement and viral pathogenesis
- (2011) Kristina A. Stoermer et al. VIROLOGY
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- (2010) Teemu T. Junttila et al. BREAST CANCER RESEARCH AND TREATMENT
- An ErbB3 Antibody, MM-121, Is Active in Cancers with Ligand-Dependent Activation
- (2010) B. Schoeberl et al. CANCER RESEARCH
- Sym004: A Novel Synergistic Anti-Epidermal Growth Factor Receptor Antibody Mixture with Superior Anticancer Efficacy
- (2010) M. W. Pedersen et al. CANCER RESEARCH
- Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM×anti-CD3) as a targeted cancer immunotherapy
- (2010) Diane Seimetz et al. CANCER TREATMENT REVIEWS
- HER3 Comes of Age: New Insights into Its Functions and Role in Signaling, Tumor Biology, and Cancer Therapy
- (2010) M. R. Campbell et al. CLINICAL CANCER RESEARCH
- Synergistic effects of CTLA-4 blockade with tremelimumab and elimination of regulatory T lymphocytes in vitro and in vivo
- (2010) Natalia Suarez et al. INTERNATIONAL JOURNAL OF CANCER
- Tumor Antigen–Targeted, Monoclonal Antibody–Based Immunotherapy: Clinical Response, Cellular Immunity, and Immunoescape
- (2010) Robert L. Ferris et al. JOURNAL OF CLINICAL ONCOLOGY
- Catumaxomab
- (2010) Rolf Linke et al. mAbs
- Signalling ballet in space and time
- (2010) Boris N. Kholodenko et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
- (2010) M. A. Curran et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tailored cancer immunotherapy using combinations of chemotherapy and a mixture of antibodies against EGF-receptor ligands
- (2010) Moshit Lindzen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Breakdown of endocytosis in the oncogenic activation of receptor tyrosine kinases
- (2009) Jasmine V. Abella et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Trastuzumab-Induced HER Reprogramming in "Resistant" Breast Carcinoma Cells
- (2009) M. Narayan et al. CANCER RESEARCH
- Strongly Enhanced Antitumor Activity of Trastuzumab and Pertuzumab Combination Treatment on HER2-Positive Human Xenograft Tumor Models
- (2009) W. Scheuer et al. CANCER RESEARCH
- Engineered therapeutic antibodies with improved effector functions
- (2009) Tsuguo Kubota et al. CANCER SCIENCE
- Complement and its role in innate and adaptive immune responses
- (2009) Jason R Dunkelberger et al. CELL RESEARCH
- Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells
- (2009) Estrella Mariel Levy et al. Innate Immunity
- Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
- (2009) Frédéric Bibeau et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer stem cells: mirage or reality?
- (2009) Piyush B Gupta et al. NATURE MEDICINE
- Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis
- (2009) T. Ben-Kasus et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- KRASMutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab
- (2008) Astrid Lièvre et al. JOURNAL OF CLINICAL ONCOLOGY
- Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu–Positive Metastatic Breast Cancer
- (2008) Antonino Musolino et al. JOURNAL OF CLINICAL ONCOLOGY
- Wild-TypeKRASIs Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
- (2008) Rafael G. Amado et al. JOURNAL OF CLINICAL ONCOLOGY
- The cancer biomarker problem
- (2008) Charles L. Sawyers NATURE
- A quantitative analysis of kinase inhibitor selectivity
- (2008) Mazen W Karaman et al. NATURE BIOTECHNOLOGY
- K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer
- (2008) Christos S. Karapetis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members
- (2008) D L Wheeler et al. ONCOGENE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started